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Abstract
Background:  Aside from muscle, brain is also a major expression site for dystrophin, the protein
whose abnormal expression is responsible for Duchenne muscular dystrophy. Cognitive
impairments are frequently associated with this genetic disease, we therefore studied the fate of
brain and skeletal muscle dystrophins and dystroglycans in dystrophic animal models.
Results:  All dystrophin-associated glycoproteins investigated were reduced in dystrophic muscle
fibres. In Dp427-deficient mdx brain and Dp71-deficient mdx-3cv brain, the expression of α-
dystroglycan and laminin was reduced, utrophin isoforms were up-regulated and β-dystroglycan
was not affected. Immunofluorescence localization of β-dystroglycan in comparison with glial,
endothelial and neuronal cell markers revealed co-localization of von Willebrand factor with β-
dystroglycan. Its expression at the endothelial-glial interface was preserved in dystrophin isoform-
deficient brain from mdx and mdx-3cv mice. In addition, chemical crosslinking revealed that the
Dp71 isoform exists in mdx brain predominantly as a monomer.
Conclusions:  This suggests an association of β-dystroglycan with membranes at the vascular-glial
interface in the forebrain. In contrast to dystrophic skeletal muscle fibres, dystrophin deficiency
does not trigger a reduction of all dystroglycans in the brain, and utrophins may partially
compensate for the lack of brain dystrophins. Abnormal oligomerization of the dystrophin isoform
Dp71 might be involved in the pathophysiological mechanisms underlying abnormal brain functions.
Background
The main hypotheses of how deficiency in dystrophin
triggers muscular dystrophy suggest that the lack of this
membrane cytoskeletal component weakens the sarco-
lemmal integrity, causes abnormal Ca2+-homeostasis
and/or impairs proper clustering of ion channel com-
plexes [1, 2]. Extensive biochemical and cell biological
studies have demonstrated that one of the major func-
tions of muscle dystrophin is to act as an actin-binding
protein which mediates a link between the extracellular
matrix component laminin and the sub-sarcolemmal
membrane cytoskeleton [3,4]. Integral or surface-associ-
ated proteins that are relatively tightly connected with
dystrophin are represented by α-,β-, γ-, and δ-sarcogly-
can [5], α- and β-dystroglycan [6], sarcospan [7], α-, β1-,
and β2-syntrophin [8], α- and β-dystrobrevin [9], lam-
inin-2 [10] and cortical actin [11]. The backbone of this
sarcolemma-spanning protein assembly is formed by the
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kDa β-dystroglycan contains a binding site for the sec-
ond half of the hinge-4 region and the cysteine-rich do-
main of Dp427 [12], thereby indirectly connecti ng the
actin membrane cytoskeleton via the amino-terminus of
the dystrophin molecule to the surface membrane [13].
Since β-dystroglycan is also tightly associated with the
peripheral merosin-binding protein α-dystroglycan, this
complex provides a stable linkage to the laminin α2-
chain in the basal lamina [10].
Deficiency in dystrophin triggers the disintegration of
complexes normally formed by the above listed sarco-
lemmal components and thereby renders muscle fibres
from patients afflicted with Duchenne muscular dystro-
phy (DMD) more susceptible to necrosis [1, 3]. In analo-
gy to the pathobiochemical findings in DMD [3, 14], the
dystrophic animal model mdx mouse also exhibits a
drastic reduction in all dystrophin-associated glycopro-
teins in bulk skeletal muscle [15, 16]. This might explain
at least partially the decreased osmotic stability [17] and
higher vulnerability of stretch-induced injury [18] in
dystrophin-deficient muscle fibres. An abnormal in-
crease in cytosolic Ca2+- levels might trigger a drastic inc
rease in net protein degradation and might be one of the
initial steps in the molecular pathogenesis of inherited
muscular dystrophy [19,20,21]. That the other members
of the dystrophin -glycoprotein complex, besides dys-
trophin, play a role in the DMD pathology, is demon-
strated by the fact that primary abnormalities in
sarcoglycans and laminin are responsible for certain
forms of limb-girdle muscular dystrophy and congenital
muscular dystrophy, respectively [5, 22]. In contrast to
muscle, much less is known about the molecular mecha-
nisms underlying brain abnormalities in the most fre-
quent neuromuscular disease in humans [23, 24]. One
factor which probably makes pathophysiological studies
of the dystrophic central nervous system more difficult is
the greater complexity of dystrophin and utrophin iso-
forms present in the brain.
Seven promoters drive the tissue-specific expression of
various dystrophin protein (Dp) isoforms from the hu-
man DMD gene [25], i.e. Dp427-M in skeletal and cardi-
ac muscle, Dp427-B in brain, Dp427-P in Purkinje
neurons, Dp-260 R in retina, Dp -140 - B/K in brain and
kidney, Dp -116-S in Schwann cells, Dp-71-B/U in brain
and many non-muscle tissues [13]. In addition, dys-
trophin-related proteins are represented by brain DRP-2
[26] and the autosomally-encoded dystrophin homo-
logue utrophin, which forms a full-length 395 kDa iso-
form (Up395) [27] and two truncated molecular species
named Up116 and Up71, also referred to as G-and U-
utrophin [28]. Besides full-length brain Dp427 and a rel-
atively low-abundance, carboxy-terminal isoform
termed brain Dp140, in the central nervous system the
major dystrophin isoform is represented by Dp71 [23].
While Dp427 was shown to be present in cortical neu-
rones, hippocampal neurones and cerebellar Purkinje
cells [29], probably mostly associated in these cell types
with the postsynaptic density [30], the two smaller dys-
trophin brain isoforms were described to be associated
with microvasular glial cells [31]. A developmental study
suggests that dystrophin expression in perivascular as-
trocytes coincides with the formation of the blood-brain
barrier [32]. Dystroglycans are also present in brain [33,
34] and a subpopulation localizes to the glial-vascular in-
terface [31]. Recently, Blake et al. [35] showed that dif-
ferent dystrobrevin isoforms are present in neuronal
versus glial dystrophin complexes. With respect to dys-
trophin-related proteins, full-length utrophin is more
widely distributed in the central nervous system [36] and
is possibly involved in the maintenance of regional spe-
cialization of the brain [37]. To complement these neuro-
biological studies and in order to determine the fate of
dystroglycans in dystrophin-deficient forebrain, we em-
ployed two established genetic animal models. The mdx
mouse is missing Dp427 due to a point mutation in exon
23 [38], while a mutation in exon 65 in the mdx-3cv
mouse affects the splicing of both the 4.8 and 14 kb dys-
trophin mRNAs resulting in the additional loss of the
Dp71 isoform [39]. Neurobehavioral studies have shown
that the dystrophic animal models used in this study ex-
hibit moderate alterations in associative learning and
deficits in long-term consolidation memory [24,
40,41,42]. Our analysis of these mutant strains indicates
that β-dystroglycan appears to be located at the endothe-
lial-glial interface in the forebrain and that not all dystro-
glycans are reduced in dystrophic brain, making it
different from dystrophic muscle fibres. Possibly an im-
paired oligomerization of the major brain Dp71 isoform
plays a role in the molecular pathogenesis in the dys-
trophic central nervous system.
Results
In contrast to muscle tissues, relatively little is known
about the function of brain dystrophins and their associ-
ated glycoproteins. To provide the necessary background
for the rationale behind this study, the complexity of the
dystrophin-glycoprotein complex, the structure and iso-
form expression pattern of dystrophins and the suitabil-
ity of dystrophic animal models is summarized in Fig. 1.
Dystrophin was previously shown to exist as a large mul-
timeric complex at the cell periphery. As illustrated in
the diagrammatic representation of Fig. 1a, the dystro-
glycan sub-complex provides the backbone structure of
this plasmalemma-spanning complex thereby providing
a linkage between the extracellular matrix and the mem-
brane cytoskeleton [3, 22]. While the Dp427(-M) isoform
exists in skeletal muscle, the central nervous system con-
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Three dystrophin isoforms exist in brain: Dp427(-B),
Dp140 and Dp71 (Fig. 1b). Since they all share carboxy-
terminal domains, antibodies against this region recog-
nize all three isoforms [23]. In order to determine the ef-
fect of the absence of dystrophin on the dystrophin-
associated glycoproteins α- and β-dystroglycan, we have
used the established animal models mdx and mdx-3cv.
These genetic models are due to a point mutation [38]
and a genetic rearrangement [39], respectively (Fig. 1c).
For comparative purposes and in order to characterize
the genetic animal models of muscular dystrophy used in
this study, the fate of dystrophin-associated glycopro-
teins was evaluated in mdx and mdx-3cv skeletal muscle
fibres and forebrain. Using indirect immunofluores-
cence microscopy, it was clearly shown that α- and β-
dystroglycan are greatly reduced in muscle cells from
both animal models. Antibodies to laminin, dystrophin,
α-sarcoglycan and both members of the dystroglycan
sub-complex almost exclusively immunolabeled the
muscle cell periphery in normal mouse (Fig. 2a,d,g,j,s).
Utrophin staining was restricted to the neuromuscular
junction region (Fig. 2m) and overlapped with the visu-
alization of the nicotinic acetylcholine receptor by α-
bungarotoxin binding (Fig. 2n). In stark contrast, in cry-
osections taken from mdx and mdx-3cv skeletal muscle,
which exhibited a complete absence of dystrophin (Fig.
2k,l), a greatly reduced immunofluorescence signal was
detectable for α- and β-dystroglycan (Fig. 2e,f,h,i), as
well as for α-sarcoglycan (Fig. 2t,u). Utrophin staining
(Fig. 2o,q), α-bungarotoxin binding (Fig. 2p,r), and lam-
inin labeling (2b, c) was not affected in dystrophic fibres.
In control experiments, cryosections were labeled with
antibodies to the membrane cytoskeletal protein spec-
trin, a component established not to be affected in mus-
cular dystrophy [14]. As can be seen in Fig. 2v-x, both
normal muscle and fibres from both dystrophic animal
models exhibit almost exclusively peripheral staining for
spectrin establishing the integrity of the cryosections an-
alysed.
Since initial immunofluorescence labeling experiments
with antibodies to β-dystroglycan resulted in a distinct
staining pattern in forebrain tissue, we performed more
detailed co-localization experiments. Double-staining
with antibodies to various common brain cell type mark-
ers revealed that this surface glycoprotein is highly en-
riched at the endothelial-glial interface in the forebrain
(Fig. 3). As labels for distinct markers of glial, neuronal
and endothelial cells we employed monoclonal antibody
NR4 against the neurofilament of apparent 68 kDa, pol-
yclonal antibody GA5 to the glial fibrillary acidic protein
and a polyclonal antibody to von Willebrand factor, re-
spectively [43, 44]. The neuronal marker strongly la-
beled this cell type but did not exhibit an overlap with the
staining pattern of β-dystroglycan (Fig. 3a). In contrast,
Figure 1
Diagrammatic representation of the dystrophin-glyc-
oprotein complex, the structure of muscle and brain
dystrophin isoforms and the genetic animal models
of muscular dystrophy. In muscle, dystrophin forms a
tightly associated complex with various surface components
which provides a stabilizing linkage between the sub-sarco-
lemmal membrane cytoskeleton and the extracellular matrix.
In panel (a) is shown the proposed spatial organization of this
peripheral complex consisting of dystrophin (Dp427), α-, β-,
γ-, and δ-sarcoglycan (SG), the sarcolemma-spanning back-
bone structure provided by α- and β-dystroglycan (DG), sar-
cospan (SS), various syntrophins (SYN) and dystrobrevins
(DB), as well as laminin-2 (LAM-2) and cortical actin. Panel
(b) outlines the various domains of dystrophin molecules
with the N-terminal actin-binding domain (AB), hinge regions
(H), the central spectrin-like rod domain (RD), as well as C-
terminal binding domains such as the WW domain, the ZZ
domain, the cysteine-rich region (CR) and the extreme car-
boxy-terminal domain (CD). While skeletal muscle fibres
contain the Dp427 isoform of dystrophin, brain tissues
express besides the full-length Dp427 molecule also two
shorter isoforms termed Dp71 and Dp140 (b). Four of the
seven promoters which drive the tissue-specific expression
of dystrophins are shown in panel (c) illustrating that a point
mutation in exon 23 or a mutation in exon 65 results in the
absence of Dp427 in mdx mice and the absence of all brain
isoforms of dystrophin in mdx-3cv mice.
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tween β-dystroglycan and the glial marker (Fig. 3b),
probably representing glial endfeet structures (Fig. 3c).
A high degree of overlapping immunolabeling was clear-
ly evident between von Willebrand factor and β-dystro-
glycan (Fig. 3d). Since antibodies to von Willebrand
factor specifically label endothelial cells, this suggests
high levels of β-dystroglycan at the endothelial-glial in-
terface. To document the specificity of the antibody used
for labeling von Willebrand factor, the restricted staining
of the endothelial layer in rat aorta is shown in Fig. 3e,f.
Following the immunolocalization of β-dystroglycan in
normal forebrain, we analysed the relative expression
levels of dystrophin and associated components by im-
munofluorescence microscopy in dystrophic forebrain.
In contrast to dystrophin (Fig. 4j-l), dystroglycan label-
ling was not reduced in cryosections from mdx or mdx-
3cv mouse forebrain. As illustrated in Fig. 4a-i, the inten-
sity and pattern of immuno staining for laminin, α-dys-
troglycan and β-dystroglycan was not affected in the
dystrophic specimens studied. Labeling with domain-
specific antibodies to dystrophin revealed the presence
of Dp71 and the absence of Dp427 in mdx forebrain,
since the antibody to the carboxy terminus showed a dis-
tinct labeling pattern (Fig. 4k) while the probe to the rod
domain did not stain any structures (not shown). All dys-
trophin isoforms which share the carboxy terminal do-
main were absent from mdx-3cv forebrain (Fig. 4l).
Utrophin exhibited a similar localization pattern to dys-
trophin and was present in the forebrain from both dys-
trophic animal models (Fig. 4m-o).
To determine potential differences in the fate of dys-
trophin-associated surface components in dystrophic
muscle and brain tissues, we also performed a compara-
tive immunoblot analysis of components of the dys-
trophin-glycoprotein complex using the established
animal models mdx and mdx-3cv. As illustrated in the
immunoblot analysis shown in Fig. 5, the expression lev-
els of laminin were not affected in the microsomal frac-
tion isolated from dystrophic mdx muscle. On the other
hand, this extracellular protein is clearly increased in its
relative density in mdx-3cv membranes (Fig. 5a). Both,
α- and β-dystroglycan, as well as α-sarcoglycan were
found to be drastically reduced in their abundance in
both dystrophic animal models (Fig. 5b-d). The dys-
trophin isoform Dp427 was demonstrated to be com-
pletely absent from mdx and mdx-3cv muscle
microsomes (Fig. 5e). These findings agree with previous
studies on the mdx mouse [15, 16, 22] and show that the
same reduction in dystrophin-associated glycoproteins
also occurs in the mdx-3cv genetic mouse model. Immu-
nolabeling of full-length utrophin of apparent 395 kDa
did not result in sufficient immuno-decoration for a
proper comparison of its expression levels in normal ver-
sus dystrophic muscle membranes (not shown). For con-
trol purposes, an identical immunoblot as was used for
the analysis of the dystrophin-glycoprotein complex, was
immuno-decorated with an antibody to the α1-subunit of
the dihydropyridine receptor. The relative abundance of
this transverse-tubular membrane protein does not
seem to be affected in microsomes isolated from dys-
trophic muscle fibres (Fig. 5f). Thus, the decrease in dys-
trophin-associated glycoproteins in skeletal muscle is a
specific resu lt of the deficiency of dystrophin, and not a
Figure 2
Immunofluorescence localization of β-dystroglycan
and associated components in skeletal muscle fibres
from dystrophic animal models. Shown are cryosections
labeled with antibodies to laminin (LAM) (a-c), α-dystrogly-
can (α-DG) (d-f), β-dystroglycan (β-DG) (g-i), the carboxy-
terminus of dystrophin (C-DYS) (j-l), utrophin (UTR) (m, o,
q), α-sarcoglycan (α-SG) (s-u), and spectrin (SPE) (v-x). Pan-
els (n), (p) and (r) represent labeling of tissue sections with
α-bungarotoxin (α-BGT). Skeletal muscle specimens were
taken from normal mice (a, d, g, j, m, n, s, v), mdx mice (b, e,
h, k, o, p, t, w) and mdx-3cv mice (c, f, i, l, q, r, u, x). Bar = 60
µm.
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trophic fibres.
Following the analysis of microsomes from dystrophic
muscle, we determined the relative expression levels of
dystrophin and associated components by immunoblot-
ting in total brain membranes. Prior to this comprehen-
sive immunoblot analysis, membrane preparations from
normal mice, mdx brain and mdx-3cv brain were com-
pared by Coomassie staining and lectin overlay assays.
Fig. 6 shows that the overall protein band pattern and
lectin staining of distinct populations of glycoproteins
was relatively comparable between the three different
preparations. The only major difference between normal
and dystrophic microsomes is the appearance of two pro-
tein bands of approximately 50 kDa in membranes iso-
lated from the mdx and the mdx-3cv disease model.
Staining with the Maclura pomifera lectin MPA and the
Tritium vulgaris lectin WGA demonstrates that the defi-
ciency in brain dystrophin isoforms does not trigger a
general reduction in microsomal glycoproteins. In con-
trast, laminin and α-dystroglycan were clearly shown to
be reduced in their relative expression in total brain mi-
crosomes from dystrophic animals, which is especially
apparent in the mdx-3cv mouse (Fig. 7a,b). Interestingly,
β-dystroglycan expression was not affected in both mdx
and mdx-3cv total brain microsomes (Fig. 7c), which is a
stark contrast to its drastic reduction in dystrophic skel-
etal muscle fibres (Fig. 5c). Since α-sarcoglycan does not
exist in brain, the abundance of members of the sarcogly-
Figure 3
Colocalization of β-dystroglycan and von Willebrand factor in normal mouse forebrain. Shown are cryosections
indirectly labeled with rhodamine-conjugated antibodies to the neurofilament of apparent 68 kDa (a), the glial fibrillary acidic
protein (b, c) and von Willebrand factor (d). Sections (a) to (d) were indirectly double-labeled with a fluorescein-conjugated
antibody against β-dystroglycan. To demonstrate the specificity of the antibody to von Willebrand factor, rat aorta sections are
shown in (e) (Haematoxylin & Eosin staining) and (f) (immunofluorescence labeled). In (a), bar = 20 µm; in (b) and (d), bar = 40
µm; in (c), bar = 10 µm; and in (e) and (f), bar = 60 µm.
BMC Cell Biology (2001) 2:2 http://www.biomedcentral.com/1471-2121/2/2can subcomplex were not studied. The immunoblot of
Fig. 7d confirms the status of the mdx-3cv brain and
demonstrates the absence of the Dp71 isoform in this an-
imal model. In analogy to previous studies on dystrophic
skeletal muscle [3], certain utrophin isoform levels were
found to be elevated in Dp427-deficient and Dp71-defi-
cient brain specimens. Both Up116 and Up71 were great-
ly increased in mdx-3cv brain microsomes (Fig. 7f,g),
while full-length utrophin did not seem to be affected in
dystrophic brain (Fig. 7e).
Since dystrophin does not exist in isolation at the cell
surface but forms tightly associated multimeric complex-
es [3], it was of interest to determine the oligomeric sta-
tus of the major brain isoform Dp71 in normal and
dystrophic mice. Using previously optimized crosslink-
ing conditions [45], we employed the hydrophilic 1.14
nm probe BS3 to stabilize high-molecular-mass com-
plexes. The Coomassie-stained gel in Fig. 8a illustrates
that incubation with the crosslinker did not trigger gen-
eral protein clustering since the protein band pattern
was relatively comparable between control and
crosslinked membranes. On the other hand, a clear dif-
ference was observed for crosslinking-stabilized Dp71
complex formation between normal and mdx brain mi-
crosomes. While the crosslinker probe induced a shift to
a high-molecular-mass complex in control samples, no
Figure 4
Immunofluorescence localization of β-dystroglycan
and associated components in forebrain from dys-
trophic animal models. Shown are cryosections labeled
with antibodies to laminin (LAM) (a-c), α-dystroglycan (α-
DG) (d-f), β-dystroglycan (β-DG) (g-i), the carboxy-terminus
of dystrophin (C-DYS) (j-l), and utrophin (UTR) (m-o). Fore-
brain specimens were taken from normal mice (a, d, g, j, m),
mdx mice (b, e, h, k, n) and mdx-3cv mice (c, f, i, l, o). Bar =
40 µm.
Figure 5
Immunoblot analysis of β-dystroglycan and associ-
ated components in normal and dystrophic skeletal
muscle fibres. Shown are identical immunoblots labeled
with antibodies to laminin (LAM) (a), α-dystroglycan (α-DG)
(b), β-dystroglycan (β- DG) (c), α-sarcoglycan (α-SG) (d),
full-length dystrophin of apparent 427 kDa (Dp427) (e), and
the α1-subunit of the dihydropyridine receptor (α1-DHPR)
(f). Lanes 1 to 3 represent microsomal membranes isolated
from normal muscle fibres, mdx fibres, and mdx-3cv fibres,
respectively. The position of immuno-decorated protein
bands is indicated by arrow heads.
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dystrophic membranes (Fig. 8b). The major dystrophin
isoform Dp71 was not detectable in mdx-3cv micro-
somes. Interestingly, crosslinking-induced complex for-
mation of full-length utrophin was observed in normal
brain, as well as in both dystrophic animal models stud-
ied (8c). Therefore, protein-protein int eractions be-
tween brain components and utrophin do not appear to
be affected in dystrophic tissues. For control purposes,
an identical immunoblot was labeled with an antibody to
the α-subunit of the Na+/K+-ATPase. No shift to an ex-
tremely high-molecular-mass complex was observed for
this brain surface protein following chemical crosslink-
ing (Fig. 8d). This strongly suggests that the decrease in
the relative electrophoretic mobility of Dp71 in normal
brain microsomes is a specific result of crosslinker-in-
duced stabilization of native membrane complexes.
Discussion
Although the X-linked inherited disorder Duchenne
muscular dystrophy (DMD) is primarily considered a
muscle disease and most patients die of respiratory or
cardiac failure [46], in a subpopulation of affected chil-
dren non-progressive mental retardation preceeds de-
generation of the muscular system [24]. These mental
abnormalities do not correlate with the stage of the mus-
cle disease [47] and can not be attributed to abnormal
motor development [46]. Since all DMD patients experi-
ence a decrease in strength of limb and torso muscles,
but only approximately one-third of dystrophic children
suffer from cognitive impairments, it is believed that dif-
ferences exist in the pathophysiolgical mechanisms be-
tween the central nervous system and muscle tissues [23,
24]. DMD children accomplish performance tasks at a
normal level, but their verbal intelligence quotient is sig-
nificantly lower as compared to age-matched normal
boys [48]. Possibly cerebral or cerebellar hypermetabo-
Figure 6
Analysis of microsomal preparations from normal, mdx and mdx-3cv brain. Shown is a Coomassie-stained gel (CB)
(a) and identical blots labeled with the Tritium vulgaris lectin WGA (b) and the Maclura pomifera lectin MPA (c). Lanes 1 to 3
represent microsomal membranes isolated from normal brain, mdx brain, and mdx-3cv brain, respectively. The relative position
of molecular mass standards (× 10-3) is indicated on the left.
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DMD patients [49], but no consistent abnormalities are
detectable in dystrophic brain tissues [50].
Based on this lack of understanding of the exact neurobi-
ology of DMD, we have performed here a comparative
analysis of the expression of dystrophins and dystrogly-
cans in brain and muscle tissues from animal models of
muscular dystrophy. Forebrain β-dystroglycan was
clearly shown to co-localize with the endothelial marker
von Willebrand factor and it is not drastically affected in
its relative abundance in brain lacking all neuronal dys-
trophin isoforms. The localization of this relatively abun-
dant glycoprotein at the endothelial-glial interface
agrees with previous immunolocalization studies on dys-
trophin-associated proteins [31, 32, 51,52,53,54]. Dys-
trophin isoforms of varying length, dystrobrevin and β-
dystroglycan appear to be enriched around blood vessels
in astrocytic endfeet in the cerebellum and at blood-ocu-
lar barrier sites in the retina [51,52,53,54]. Here we can
show that the cellular localization of this integral mem-
brane component at the endothelial-glial interface is nei-
Figure 7
Immunoblot analysis of β dystroglycan and associ-
ated components in normal and dystrophic brain-
membranes. Shown are identical immunoblots labeled with
antibodies to laminin (LAM) (a), α-dystroglycan (α-DG) (b),
β-dystroglycan (β-DG) (c), dystrophin of apparent 71 kDa
(Dp71) (d), full-length utrophin of apparent 395 kDa (Up395)
(e), the utrophin isoform of apparent 116 kDa (Up116) (f),
and the utrophin isoform of apparent 71 kDa (Up71) (g).
Lanes 1 to 3 represent microsomal membranes isolated from
normal brain, mdx brain, and mdx-3cv brain, respectively. The
position of immuno-decorated protein bands is indicated by
arrow heads.
Figure 8
Chemical crosslinking analysis of brain dystrophin
isoform Dp71 in normal and mdx mice. Shown is a
Coomassie-stained gel (a) and identical immunoblots labeled
with antibodies to the dystrophin isoform of apparent 71
kDa (Dp71) (b), full-length utrophin of apparent 395 kDa
(Up395) (c), and the α-subunit of the Na+/K+-ATPase (α-
NKA) (d). Lanes 1, 3 and 5 represent untreated control sam-
ples (-) and lanes 2, 4 and 6 are membranes treated with 200
µg crosslinker BS3 per mg protein (+). Lanes 1 and 2, 3 and 4,
and 5 and 6 represent microsomal membranes isolated from
normal brain, mdx brain, and mdx-3cv brain, respectively. The
position of immuno-decorated monomers is indicated by
closed arrow heads and crosslinking-stabilized high-molecu-
lar-mass complexes marked by open arrows. The relative
position of molecular mass standards (× 10-3) is indicated on
the left.
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Dp71-deficient mdx-3cv forebrain. Thus, in contrast to
dystrophic mdx and DMD skeletal muscle fibres, which
show a greatly reduced expression of sarcolemmal β-dys-
troglycan [3, 15, 16], this usually dystrophin-associated
glycoprotein experiences a different fate during patho-
physiological changes in the central nervous system of
dystrophic mice. However, the relative expression of α-
dystroglycan is reduced in dystrophic brain. This is unex-
pected, since both α- and β-dystroglycan are produced
by post-translational cleavage of the product of a single
transcript [10]. Although β-dystroglycan expression is
preserved, this integral membrane protein might not be
properly positioned in order to anchor extracellular α-
dystroglycan to the outside of the membrane. Compen-
satory mechanisms to counteract the loss of dystrophin
isoforms may induce conformational changes in β-dys-
troglycan units that interfere with stablising interactions
within dystroglycan sub-complexes. Therefore, the pres-
ervation of β-dystroglycan does not seem to rescue the
extracellular dystroglycan form.
Possibly up-regulation of utrophin isoforms partially
compensates for the lack of brain dystrophins and there-
by helps anchoring β-dystroglycans. This idea agrees
with previous studies of extraocular muscle fibres from
mdx and mdx-utrn -/- mice [55, 56]. In contrast to the
neuromuscular junction-specific localization of utrophin
in normal skeletal muscle [55], in dystrophin-deficient
mdx extraocular muscle the full-length isoform of
utrophin of apparent 395 kDa is up-regulated in its rela-
tive expression and also found in n on-junctional regions
of the sarcolemma [57]. This replacement of dystrophin
Dp427 by the large utrophin isoform seems to spare a
large proportion of the extraocular muscle population
from degeneration. However, mdx-utrn -/- mice lacking
both dystrophin and utrophin exhibit severe dystrophic
changes in these muscle groups strongly suggesting that
the endogenous up-regulation of utrophin protects ex-
traocular muscle in dystrophinopathies [58]. A similar
protective mechanism might occur in dystrophic brain
regions. We could previously show that most members of
the dystrophin super-family of proteins, which share the
carboxy-terminal binding domain for β-dystroglycan,
exhibit very comparable biochemical properties [59, 60].
This was also confirmed for brain isoforms of dystrophin
[61]. Since brain utrophins co-localize with the dystro-
glycan sub-complex in the forebrain, it seems likely that
an up-regulation of utrophins anchors these components
in Dp427- or Dp71-deficient membranes. Dp71 alone
does not appear to properly oligomerize and anchor dys-
troglycans in mdx brain. Although Dp71 co-localizes with
β-dystroglycan, the lack of full-length brain dystrophin
seems to trigger a disturbed organization of the dystro-
glycan sub-complex resulting in a drastic reduction in
the extracellular dystroglycan isoform. These findings
show that we still have an incomplete understanding of
the individual functions of dystrophin isoforms and of
the interaction between short and long dystrophins in
different tissues.
In contrast to established changes in the expression of
dystrophins and utrophins in dystrophic brain
[23,30,62], relatively little is known about the fate of
dystrophin/utrophin-associated glycoproteins in human
DMD brain. In contrast to mdx brain, DMD patient spec-
imens appear to exhibit a reduction in β-dystroglycan
levels [16, 63]. However, representative surveys of large
patient populations with a varying degree of mental re-
tardation have not yet been performed making it difficult
to compare findings from genetic animal models with
patient data. In this respect, the finding presented in this
study that the major brain dystrophin isoform Dp71 does
not appear to properly oligomerize in mdx brain might
also be relevant for the human disease condition. The
lack of crosslinker-induced complex stabilization indi-
cates that Dp71 might trigger abnormal anchoring of dys-
troglycans, although it is present at normal
concentrations. This in turn might destabilize certain
brain structures and/or signal transduction pathways
normally relying on the integrity of brain dystrophin-
glycoprotein complexes. Since Ca2+-levels were found to
be abnormal in dystrophic brain [64], similar patho-
physiological changes, as suggested to be involved in
muscular degeneration [19,20,21], could also render cer-
tain brain cells more susceptible to necrosis. An in-
creased influx of Ca2+-ions might trigger cell destruction
not only in Dp71-deficient cells but also in cellular struc-
tures with Dp71 molecules not capable of properly form-
ing complexes with β-dystroglycan. In the dystrophic
forebrain, abnormal anchoring of dystroglycans might
therefore effect the proper establishment of the blood-
brain barrier. However, since the cognitive impairment
in DMD is non-progressive and exhibits great variations
between individual patients, only a sub-population of
brain cells may be affected by this pathophysiological
mechanism. Deletions in the exon 45-52 region of the
DMD gene have been reported to be associated with an
increased incidence of cognitive abnormalities [24]. In
these patients only the expression of the Dp 427 and
Dp140 isoforms is impaired, but not the Dp71 protein
[65]. Thus, probably a combination of different primary
genetic defects in the DMD gene and variations in com-
pensatory mechanisms result in the different degrees of
mental insufficiencies in dystrophic children.
Conclusions
In conclusion, this report demonstrates that β-dystrogly-
can is not present at high concentrations in central neu-
rons of the forebrain region, but seems to be mostly
BMC Cell Biology (2001) 2:2 http://www.biomedcentral.com/1471-2121/2/2located at the interface between endothelial cells and
glia. These structures possibly represent endfeet on as-
trocytes at the blood-brain barrier. In dystrophic fore-
brain, β-dystroglycan expression is not drastically
affected, possibly due to the up-regulation of utrophin
isoforms which partially compensate for the deficiency in
brain dystrophins. Chemical crosslinking analysis
showed that Dp71 exists in contrast to its normally oligo-
meric form in mdx brain as a monomeric protein. Thus,
the lack in brain dystrophins does not necessarily lead to
a loss in all associated glycoproteins and possibly abnor-
mal oligomerization of the brain dystrophin might play a
role in the molecular pathogenesis of abnormal brain
functions in muscular dystrophy.
Materials and methods
Materials
Fluorescein-, rhodamine- or peroxidase-conjugated sec-
ondary antibodies were purchased from Boehringer
Mannheim (Lewis, East Sussex, UK). Commercially
available primary antibodies were from Novocastra Lab-
oratories Ltd. (Newcastle upon Tyne, UK), Upstate Bio-
technology (Lake Placid, NY, USA) and Sigma Chemical
Company (Poole, Dorset, UK), and Texas Red-labeled α-
bungarotoxin was purchased from Molecular Probes Eu-
rope BV (Leiden, The Netherlands). Superfrost Plus pos-
itively-charged microscope slides were from Menzel
Glaesser (Braunschweig, Germany). Fuji Neopan
400ASA B/W photographic film was obtained from Fuji
Photo Film Co. (Tokyo, Japan) and Kodacolor Gold
400ASA VR film from Eastman Kodak Company (Ro-
chester, NY). Protease inhibitors and acrylamide were
purchased from Boehringer Mannheim (Lewis, East Sus-
sex, UK). Peroxidase-conjugated lectins were purchased
from EY Labs (San Mateo, CA, USA). Western blotting
chemiluminescence substrates and chemical crosslink-
ers were obtained from Pierce & Warriner (Chester,
Cheshire, UK). Immobilon-P nitrocellulose was from
Millipore Corporation (Bedford, MA, USA). All other
chemicals were of analytical grade and purchased from
Sigma Chemical Company (Poole, Dorset, UK).
Antibodies
Monoclonal and polyclonal antibodies employed in this
study were characterized as previously described [66,
67]. Monoclonal antibodies NCL-43 against β-dystrogly-
can, NCL-a-SARC against α-sarcoglycan, DYS-1 to the
Dp427 rod-domain, DYS-2 to the Dp427 carboxy-termi-
nus, NCL-DRP1 to the carboxy -terminus of full-length
utrophin and NCL-SPEC2 against spectrin were from
Novocastra Laboratories Ltd. (Newcastle upon Tyne,
UK). Monoclonal antibodies VIA41 to α-dystroglycan
and c464.6 to the α-subunit of the Na+/K+-ATPase were
purchased from Upstate Biotechnology (Lake Placid, NY,
USA). Polyclonal antibodies to von Willebrand factor,
laminin and the glial fibrillary acidic protein, as well as
monoclonal antibody NR4 to the neurofilament of ap-
parent 68 kDa were obtained from Sigma Chemical
Company (Poole, Dorset, UK). A polyclonal antibody
which recognizes the carboxy-terminal domain of the
utrophin isoforms Up395, Up116 and Up71 [68] was a
generous gift of Dr. Steve Winder (University of Glas-
gow). Monoclonal antibody IIID5 against the α1-subunit
of the dihydropyridine receptor was a generous gift of Dr.
Kevin P. Campbell (University of Iowa, Iowa City, IA). An
antibody to the extreme carboxy-terminus of α-sarcogly-
can was raised by 4 monthly injections of a peptide rep-
resenting the last 15 residues of the carboxy-terminus
[69] using a standard immunization protocol [70]. The
peptide had been synthesized and coupled to KLH carri-
er by Research Genetics (Huntington, AL).
Animal models
Muscle and brain samples from the mdx mouse, which
lacks the Dp427 isoform of dystrophin due to a point mu-
tation in exon 23 [38], and from the mdx-3cv mouse,
which has a mutation in exon 65 that affects the splicing
of both the 4.8 and 14 kb dystrophin mRNAs causing a
loss of all dystrophin isoforms including the major brain
dystrophin isoform Dp71 [39], were a generous gift from
Dr. Harald Jockusch (Department of Developmental Bi-
ology, University of Bielefeld, Germany). For immun-
ofluorescence microscopy, tissue specimens were taken
from the tibialis anterior muscle and the forebrain re-
gion, quick-frozen in liquid nitrogen-cooled isopentane,
transported on dry ice and stored at -70°C prior to cryo-
sectioning. For immunoblot analysis, total brain and
bulk skeletal muscle were dissected, quick-frozen in liq-
uid nitrogen, transported in a container with dry ice and
then stored at -70°C prior to homogenization.
Immunofluorescence microscopy
For immunolabeling of muscle and brain tissue sections,
12 µm cryosections were prepared using a standard cry-
ostat (Microm, Heidelberg, Germany) and mounted on
Superfrost Plus positively-charged microscope slides.
Fixation, blocking, incubation with primary antibodies,
washing steps, incubation with secondary antibodies, as
well as photography was performed by established meth-
odology [55]. Photographs were taken on Fuji Neopan
400ASA B/W photographic film or Kodak Gold Koda-
color 400ASA VR film. For double-staining procedures,
a mixture of the appropriate primary antibodies were ap-
plied to tissue sections for 1 h at 37°C, cryosections
washed, and then separately incubated for 30 min each
with the appropriate secondary antibodies. In case of an-
tibodies which had been generated in the same animal
species, photographic images were obtained from con-
current areas in serial sections, and the labeling results
overlayed.
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In order to compare the relative expression levels of
members of the dystrophin-glycoprotein complex by im-
munoblotting, established protocols for the isolation of
microsomal membranes from skeletal muscle [45] and
brain [71] were employed. To minimize proteolytic deg-
radation of membrane proteins, all buffers contained a
protease inhibitor cocktail (0.2 mM pefabloc, 1.4 µM
pepstatin, 0.15 µM aprotinin, 0.3 µM E-64, 1 µM leupep-
tin, 0.5 µM soybean trypsin inhibitor, and 1 mM EDTA)
and all procedures were performed in a cold room at 0-
4°C. Membrane pellets were resuspended at a protein
concentration of 10 mg/ml and used immediately for gel
electrophoretic analysis or quick-frozen in liquid nitro-
gen and then stored at -70°C prior to further usage. Pro-
tein concentration was determined by the method of
Bradford [72] using bovine serum albumin as a standard.
Chemical crosslinking analysis
Chemical crosslinking was performed as previously de-
scribed in detail [45, 66]. Microsomes (1 mg protein)
were diluted to a final volume of 500 µl with 50 mM
HEPES, pH 8.0 at 25°C. Using a stock solution of 5 mg/
ml chemical crosslinker, bis-sulfosuccinimidyl-suberate
(BS3) was added to the membrane suspension at a final
concentration of 200 µg cross-linker per mg membrane
protein. Since the cross -linker BS3 is water-soluble, it
was dissolved in 50 mM citrate buffer, pH 5.0 in order to
retard hydrolysis. Samples were incubated for 30 min
with constant agitation at 25°C and then the crosslinking
reactions terminated by the addition of 50 µl of 1 M am-
monium acetate per ml reaction mixture. An equal vol-
ume of reducing sample buffer [73] was added and the
solution incubated for 15 min at 37°C before being sub-
jected to electrophoretic separation.
Gel electrophoresis, lectin staining and immunoblotting
Gel electrophoretic separation using 5% or 7% (w/v) re-
solving gels with a 5% (w/v) stacking gel in the presence
of sodium dodecyl sulfate and dithiotreitol was per-
formed for 200 Vh employing a Mini-MP3 electrophore-
sis system from Bio-Rad Laboratories (Hempel
Hempstead, Herts., UK), whereby 25 µg protein was
loaded per well [66, 73]. Chemically crosslinked samples
were separated on gels lacking a stacking gel system. Ni-
trocellulose replica of polyacrylamide gels were pro-
duced as described by Towbin et al. [74]. Blot overlays
with peroxidase-conjugated lectins (MPA, Maclura
pomifera lectin; WGA, Tritium vulgaris lectin) were car-
ried out as previously described [75]. For immunolabe-
ling, nitrocellulose sheets were blocked and incubated
with primary and secondary antibodies as previously de-
scribed [45]. Immunodecoration was evaluated by the
enhanced chemiluminescence technique [76]. Densito-
metric scanning of enhanced chemiluminescence blots
was performed on a Molecular Dynamics 300S comput-
ing densitometer (Sunnyvale, CA) with ImageQuant
V3.0 software.
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